Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FER | P16591 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYBB | P04839 | 2/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28588443 | 0.82 | GSK3B (0.50) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL3662540 | 0.80 | IDO1 (0.40) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL20751705 | 0.80 | MAOA (0.34) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL982942 | 0.80 | ALDH1A1 (0.39) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL7088055 | 0.80 | MAOA (0.34) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL1858902 | 0.80 | ALDH1A1 (0.39) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL181764 | 0.76 | LRRK2 (0.59) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL30462618 | 0.76 | LRRK2 (0.59) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL17816635 | 0.76 | LRRK2 (0.59) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL2051642 | 0.74 | ALDH1A1 (0.33) | MAOAMAOBPDGFRAFERLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4258116-A | ORGANIC SEMICONDUCTOR | CANON KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | claimed |
| US-20110160246-A1 | Neurodegenerative Protein Aggregation Inhibition Methods and Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-7923230-B2 | Diminishing presence of protein aggregates in an environment susceptible to formation of protein aggregate by introducing into environment a compound having two domains, a first domain that binds to protein aggregation having two monomers, and a second domain binding to diminishing protein | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7485706-B2 | Neurodegenerative protein aggregation inhibition methods and compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080182792-A1 | NEURODEGENERATIVE PROTEIN AGGREGATION INHIBITION METHODS AND COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-31 | — | — | US | disclosed |
| US-20050209173-A1 | Neurodegenerative protein aggregation inhibition methods and compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-09-22 | — | — | US | disclosed |
| WO-2005011610-A2 | NEURODEGENERATIVE PROTEIN AGGREGATION INHIBITION METHODS AND COMPOUNDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6518394-B2 | Polyaniline, oxidation or electrochemical, aromatic amine initiator which reacts and becomes part of the polymer chain | DREXEL UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20010037947-A1 | End-functionalized aniline-based oligomers, corrosion-resistant copolymers and methods of making the same | WEI YEN (US) | 2001-11-08 | — | — | US | disclosed |
| US-20010034421-A1 | End-functionalized aniline-based oligomers, corrosion-resistant copolymers and methods of making the same | WEI YEN (US) | 2001-10-25 | — | — | US | disclosed |
| US-6239251-B1 | FORMING IMINE END GROUPS BY REACTION WITH AN ALDEHYDE | DREXEL UNIVERSITY | 2001-05-29 | — | — | US | disclosed |
| WO-1997014729-A9 | END-FUNCTIONALIZED ANILINE-BASED OLIGOMERS, CORROSION-RESISTANT COPOLYMERS AND METHODS OF MAKING THE SAME | — | 1997-08-07 | — | — | WO | disclosed |
| WO-1997014729-A1 | END-FUNCTIONALIZED ANILINE-BASED OLIGOMERS, CORROSION-RESISTANT COPOLYMERS AND METHODS OF MAKING THE SAME | DREXEL UNIVERSITY (US) | 1997-04-24 | — | — | WO | disclosed |
| US-4258116-A | ORGANIC SEMICONDUCTOR | CANON KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037947-A1 | End-functionalized aniline-based oligomers, corrosion-resistant copolymers and methods of making the same | MAOA, OGG1, AAAS | MAOA 1/4885MAOB 9/4885PDGFRA 4147/4885 |
| US-20010034421-A1 | End-functionalized aniline-based oligomers, corrosion-resistant copolymers and methods of making the same | MAOA, OGG1, AAAS | MAOA 1/4885MAOB 9/4885PDGFRA 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.